Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2- breast cancer. Xiao Y, Yang F, Qi YJ, Chen L, et al. J Clin Invest 2026;136:e202305.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xiao Y, Yang F, Qi YJ, Chen L, et al. Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2- breast cancer. J Clin Invest 2026;136:e202305.
PMID: 42878074